glp-1 cardiovascular outcomes 2025 news Agonists in Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Frontiers | A decade of

Clinical trial data from the STEP 1 extension study showed that after discontinuing semaglutide 2.4 mg, approximately two-thirds of weight loss was regained within one year

Retatrutide Dosing: What You Need to Know Before Taking It Retatrutide is an investigational triple agonist medication generating significant interest for obesity and type 2 diabetes management

Is there a genetic test for GLP-1 response

Frequently Asked Questions What is a lower body lift after gastric bypass

In addition, recurrent hypoglycemia exacerbates the defective responses to subsequent hypoglycemia, thus leading to a vicious circle of reduced awareness, increased vulnerability and further episodes of hypoglycemia (Figure 13.7)

9 These clinical findings are consistent with preclinical data that berberine activates AMPK and favorably alters lipid metabolism, but the trial did not directly measure GLP-1 or gut microbiota composition